6 assets in Chronic Neutrophilic Leukemia

Therapeutic assets addressing Chronic Neutrophilic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Azacitidine Chronic Neutrophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Pevonedistat Chronic Neutrophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Venetoclax Chronic Neutrophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)